학술논문

Homozygous TBC1 domain-containing kinase (TBCK) mutation causes a novel lysosomal storage disease - a new type of neuronal ceroid lipofuscinosis (CLN15)?
Document Type
Academic Journal
Source
Acta Neuropathologica Communications. December 27, 2018, Vol. 6 Issue 1
Subject
Language
English
ISSN
2051-5960
Abstract
Homozygous mutation of TBC1 domain-containing kinase (TBCK) is the cause of a very recently defined severe childhood disorder, which is characterized by severe hypotonia, global developmental delay, intellectual disability, epilepsy, characteristic facies and premature death. The link between TBCK loss of function and symptoms in patients with TBCK deficiency disorder (TBCK-DD) remains elusive. Here we demonstrate for the first time the histopathological characteristics of TBCK deficiency consisting of 1) a widespread and massive accumulation of lipofuscin storage material in neurons of the central nervous system without notable neuronal degeneration, 2) storage deposits in few astrocytes, 3) carbohydrate-rich deposits in brain, spleen and liver and 4) vacuolated lymphocytes. Biochemical examinations ruled out more than 20 known lysosomal storage diseases. These investigations strikingly uncover TBCK-DD as a novel type of lysosomal storage disease which is characterized by different storage products rather than one specific type of accumulated material. Due to the clear predominance of intraneuronal lipofuscin storage material and the characteristic clinical presentation we propose to classify this disease as a new subtype of neuronal ceroid lipofuscinosis (CLN15). Our results and previous reports suggest an autophagosomal-lysosomal dysfunction caused by enhanced mTORC1-mediated autophagosome formation and reduced Rab-mediated autophagosome-lysosome fusion, thus disclosing potential novel targets for therapeutic approaches in TBCK-DD. Keywords: Infantile muscular hypotonia with psychomotor retardation and characteristic facies 3 (IHPRF3), Central nervous system (CNS), Vacuolated lymphocytes, Autophagy, Mammalian target of rapamycin (mTOR), Rab
Author(s): Stefanie Beck-Wödl[sup.1] , Klaus Harzer[sup.2] , Marc Sturm[sup.1] , Rebecca Buchert[sup.1] , Olaf Riess[sup.1] , Hans-Dieter Mennel[sup.4] , Elisabeth Latta[sup.3] , Axel Pagenstecher[sup.4] and Ursula Keber[sup.4] Introduction Homozygous mutation [...]